Clinical trials: Adherence, Treatment
HIV
DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
Darunavir is a nonpeptidic protease inhibitor with a high genetic barrier to resistance that evolved from a prototype compound synthesized using structure-based design strategies.
- Trial name
- DRIVESHAFT (NCT01423812)
- Testing
- Twice-daily combination Darunavir and ritonavir, Once-daily combination Darunavir and ritonavir
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ruth M. Rothstein CORE Center
Heart Failure
Targeted Intervention to Improve Medication Adherence in Cognitively Impaired Patients With HF (TARGET)
Trialing an automated medication dispensing device (AMDD) to improve medication adherence in patients with heart failure.
- Trial name
- TARGET (NCT01602731)
- Testing
- Automated Medication Dispensing Device
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- VA Office of Research and Development